Trial | NCT04650763  Report issue

Title

Bone Healing in Immediate Dental Implants
Effect of PRP on Bone Healing in Immediate Implants Analyzed by CBCT

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    PRP injection ...

  • Study Participants

    12
To study the effect of platelet-rich plasma concentrate on marginal bone loss and bone mineral density in immediate implant placement through CBCT.
12 subjects were equally categorized into two groups. Group, I was the control group; whereas, the subjects in Group II received Platelet Rich Plasma (PRP) therapy. All subjects were given a standard treatment with single implant system. Inserted implants were analyzed through Cone Beam Computerized Tomography (CBCT). Records were registered at the baseline, at 12th week before functional loading and 26th week after functional loading.
Study Started
Oct 02
2017
Primary Completion
Mar 30
2018
Study Completion
Mar 30
2018
Last Update
Dec 03
2020

Biological PRP injection

PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.

  • Other names: Platelet Rich Plasma injection

Device Automated blood cell separator to extract PRP

Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.

  • Other names: Automated blood cell separator/ centrifuge

Control Group No Intervention

Dental implant was placed in these patients following full protocol of immediate implant placement.

PRP Group Experimental

In this group Platelet Rich Plasma (PRP) was injected in soft tissue over surgical site.

Criteria 

Inclusion Criteria:

patients maintaining good oral hygiene, having adequate bone quantity at the implant site, uneventful extraction

Exclusion Criteria:

Active infection around implant site, immunocompromised state, with current major systemic disease (uncontrolled diabetes, rheumatoid arthritis, etc.) or oral pathologies, history of bleeding disorders or on anticoagulant therapy, or patients on bisphosphonates were excluded from the study
No Results Posted